Lupin Limited has informed the Exchange about Lupin Healthcare (UK) Limited, a wholly owned subsidiary of the Company having acquired the entire share capital of Renascience Pharma Limited, United Kingdom.
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.9 pts more than Nifty Midcap 150 and 1.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Lupin Limited announced that its wholly owned UK subsidiary, Lupin Healthcare (UK) Limited, has acquired the entire share capital of Renascience Pharma Limited, based in the United Kingdom. The deal was completed through the subsidiary route, meaning Lupin now has full ownership of the UK-based Renascience Pharma. No financial details such as deal value, revenue contribution, or strategic rationale have been disclosed in this filing. This expands Lupin's UK and European footprint through inorganic growth.
This is a subsidiary-level acquisition that strengthens Lupin's UK presence, but the lack of disclosed deal value or business details limits immediate assessment. Shareholders should watch for further disclosures on deal size, Renascience's product portfolio, and revenue contribution to gauge the strategic value.